Keit Men Wong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Keit Men Wong has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Bogdan Beirowski
Department of Neurology, The Neuroscience Research Institute, College of Medicine, The Ohio State University Wexner Medical Center
5 shared publications - Joan Susan Baizer
Department of Physiology and Biophysics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, USA
5 shared publications Chet C. Sherwood
Department of Anthropology, The George Washington University, Washington, DC
3 shared publications- Elisabetta Babetto
Department of Neurology, The Neuroscience Research Institute, College of Medicine, The Ohio State University Wexner Medical Center
3 shared publications Patrick R. Hof
Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York
3 shared publicationsSandra F. Witelson
Department of Psychiatry and Behavioural Neurosciences, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, L8S 4K1, Canada
3 shared publications
Latest Publications
- Open Access
- 4 March 2026
- Published by Wiley in European Journal of Neuroscience
- Vol. 63 (5)
Fidelity of Sensory Reinnervation in Peroneal and Sural Nerves to Lumbar Dorsal Root Ganglia 4 and 5 After Segmental Injury to the Sciatic Nerve
Recovery after axotomy of a peripheral nerve is dependent on regrowth of axons from the point of injury to distal sensorimotor tissues and can be complicated by nerve branching. Little is known about regeneration of sensory axons that encounter branch points distal to injuries. The experiments reported here focused on this question and sought to assess the fidelity of sensory axon regeneration, where fidelity is defined as an axon that originally innervated a distal branch of the sciatic nerve regenerated into that same distal branch after injury, with serial retrograde labeling. Rats with segmental sciatic nerve injuries were treated with linear or branched grafts, with retrograde labels injected into the peroneal and sural branches of the sciatic nerve prior to injury and 12 weeks after. Lumbar dorsal root ganglia 4 and 5 were collected after 12 weeks and were imaged to determine the fidelity of sensory axon regeneration. Results show that the fidelity of sensory regeneration into these two branches differed by the branch and the graft type. Interestingly, the fidelity of sensory axon reinnervation was greater into the peroneal nerve, which is a mixed sensorimotor nerve, compared to the sural nerve, which is a sensory nerve. This occurred in both graft types and suggests that the fidelity of sensory regeneration is improved into mixed branches distal to the PNI compared to sensory branches and supports why regeneration of segmental branched defects may be superior using anatomically matching branched grafts.
- 4 March 2026
- Published by Wiley in European Journal of Neuroscience
- Vol. 63 (5)
Open AccessFidelity of Sensory Reinnervation in Peroneal and Sural Nerves to Lumbar Dorsal Root Ganglia 4 and 5 After Segmental Injury to the Sciatic Nerve
Recovery after axotomy of a peripheral nerve is dependent on regrowth of axons from the point of injury to distal sensorimotor tissues and can be complicated by nerve branching. Little is known about regeneration of sensory axons that encounter branch points distal to injuries. The experiments reported here focused on this question and sought to assess the fidelity of sensory axon regeneration, where fidelity is defined as an axon that originally innervated a distal branch of the sciatic nerve regenerated into that same distal branch after injury, with serial retrograde labeling. Rats with segmental sciatic nerve injuries were treated with linear or branched grafts, with retrograde labels injected into the peroneal and sural branches of the sciatic nerve prior to injury and 12 weeks after. Lumbar dorsal root ganglia 4 and 5 were collected after 12 weeks and were imaged to determine the fidelity of sensory axon regeneration. Results show that the fidelity of sensory regeneration into these two branches differed by the branch and the graft type. Interestingly, the fidelity of sensory axon reinnervation was greater into the peroneal nerve, which is a mixed sensorimotor nerve, compared to the sural nerve, which is a sensory nerve. This occurred in both graft types and suggests that the fidelity of sensory regeneration is improved into mixed branches distal to the PNI compared to sensory branches and supports why regeneration of segmental branched defects may be superior using anatomically matching branched grafts.
- Open Access
- 1 March 2026
- Vol. 63 (5) , e70420
Fidelity of Sensory Reinnervation in Peroneal and Sural Nerves to Lumbar Dorsal Root Ganglia 4 and 5 After Segmental Injury to the Sciatic Nerve.
Recovery after axotomy of a peripheral nerve is dependent on regrowth of axons from the point of injury to distal sensorimotor tissues and can be complicated by nerve branching. Little is known about regeneration of sensory axons that encounter branch points distal to injuries. The experiments reported here focused on this question and sought to assess the fidelity of sensory axon regeneration, where fidelity is defined as an axon that originally innervated a distal branch of the sciatic nerve regenerated into that same distal branch after injury, with serial retrograde labeling. Rats with segmental sciatic nerve injuries were treated with linear or branched grafts, with retrograde labels injected into the peroneal and sural branches of the sciatic nerve prior to injury and 12 weeks after. Lumbar dorsal root ganglia 4 and 5 were collected after 12 weeks and were imaged to determine the fidelity of sensory axon regeneration. Results show that the fidelity of sensory regeneration into these two branches differed by the branch and the graft type. Interestingly, the fidelity of sensory axon reinnervation was greater into the peroneal nerve, which is a mixed sensorimotor nerve, compared to the sural nerve, which is a sensory nerve. This occurred in both graft types and suggests that the fidelity of sensory regeneration is improved into mixed branches distal to the PNI compared to sensory branches and supports why regeneration of segmental branched defects may be superior using anatomically matching branched grafts.
- 1 March 2026
- Vol. 63 (5) , e70420
Open AccessFidelity of Sensory Reinnervation in Peroneal and Sural Nerves to Lumbar Dorsal Root Ganglia 4 and 5 After Segmental Injury to the Sciatic Nerve.
Recovery after axotomy of a peripheral nerve is dependent on regrowth of axons from the point of injury to distal sensorimotor tissues and can be complicated by nerve branching. Little is known about regeneration of sensory axons that encounter branch points distal to injuries. The experiments reported here focused on this question and sought to assess the fidelity of sensory axon regeneration, where fidelity is defined as an axon that originally innervated a distal branch of the sciatic nerve regenerated into that same distal branch after injury, with serial retrograde labeling. Rats with segmental sciatic nerve injuries were treated with linear or branched grafts, with retrograde labels injected into the peroneal and sural branches of the sciatic nerve prior to injury and 12 weeks after. Lumbar dorsal root ganglia 4 and 5 were collected after 12 weeks and were imaged to determine the fidelity of sensory axon regeneration. Results show that the fidelity of sensory regeneration into these two branches differed by the branch and the graft type. Interestingly, the fidelity of sensory axon reinnervation was greater into the peroneal nerve, which is a mixed sensorimotor nerve, compared to the sural nerve, which is a sensory nerve. This occurred in both graft types and suggests that the fidelity of sensory regeneration is improved into mixed branches distal to the PNI compared to sensory branches and supports why regeneration of segmental branched defects may be superior using anatomically matching branched grafts.
- Open Access
- 19 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (14) , 11665
Evaluation of Novel Enhancer Compounds in Gentamicin-Mediated Readthrough of Nonsense Mutations in Rett Syndrome
Rett syndrome (RTT), a severe X-linked neurodevelopmental disorder, is primarily caused by mutations in the methyl CpG binding protein 2 gene (MECP2). Over 35% RTT patients carry nonsense mutation in MECP2, making it a suitable candidate disease for nonsense suppression therapy. In our previous study, gentamicin was found to induce readthrough of MECP2 nonsense mutations with modest efficiency. Given the recent discovery of readthrough enhancers, CDX compounds, we herein evaluated the potentiation effect of CDX5-1, CDX5-288, and CDX6-180 on gentamicin-mediated readthrough efficiency in transfected HeLa cell lines bearing the four most common MECP2 nonsense mutations. We showed that all three CDX compounds potentiated gentamicin-mediated readthrough and increased full-length MeCP2 protein levels in cells expressing the R168X, R255X, R270X, and R294X nonsense mutations. Among all three CDX compounds, CDX5-288 was the most potent enhancer and enabled the use of reduced doses of gentamicin, thus mitigating the toxicity. Furthermore, we successfully demonstrated the upregulation of full-length Mecp2 protein expression in fibroblasts derived from Mecp2R255X/Y mice through combinatorial treatment. Taken together, findings demonstrate the feasibility of this combinatorial approach to nonsense suppression therapy for a subset of RTT patients.
- 19 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (14) , 11665
Open AccessEvaluation of Novel Enhancer Compounds in Gentamicin-Mediated Readthrough of Nonsense Mutations in Rett Syndrome
Rett syndrome (RTT), a severe X-linked neurodevelopmental disorder, is primarily caused by mutations in the methyl CpG binding protein 2 gene (MECP2). Over 35% RTT patients carry nonsense mutation in MECP2, making it a suitable candidate disease for nonsense suppression therapy. In our previous study, gentamicin was found to induce readthrough of MECP2 nonsense mutations with modest efficiency. Given the recent discovery of readthrough enhancers, CDX compounds, we herein evaluated the potentiation effect of CDX5-1, CDX5-288, and CDX6-180 on gentamicin-mediated readthrough efficiency in transfected HeLa cell lines bearing the four most common MECP2 nonsense mutations. We showed that all three CDX compounds potentiated gentamicin-mediated readthrough and increased full-length MeCP2 protein levels in cells expressing the R168X, R255X, R270X, and R294X nonsense mutations. Among all three CDX compounds, CDX5-288 was the most potent enhancer and enabled the use of reduced doses of gentamicin, thus mitigating the toxicity. Furthermore, we successfully demonstrated the upregulation of full-length Mecp2 protein expression in fibroblasts derived from Mecp2R255X/Y mice through combinatorial treatment. Taken together, findings demonstrate the feasibility of this combinatorial approach to nonsense suppression therapy for a subset of RTT patients.
- 27 June 2022
- Published by Oxford University Press (OUP) in Brain
- Vol. 145 (9) , 3022-3034
Mutations inTAF8cause a neurodegenerative disorder
TAF8 is part of the transcription factor II D complex, composed of the TATA-binding protein and 13 TATA-binding protein–associated factors (TAFs). Transcription factor II D is the first general transcription factor recruited at promoters to assemble the RNA polymerase II preinitiation complex. So far disorders related to variants in 5 of the 13 subunits of human transcription factor II D have been described. Recently, a child with a homozygous c.781-1G>A mutation in TAF8 has been reported. Here we describe seven further patients with mutations in TAF8 and thereby confirm the TAF8 related disorder. In two sibling patients, we identified two novel compound heterozygous TAF8 splice site mutations, c.45+4A > G and c.489G>A, which cause aberrant splicing as well as reduced expression and mislocalization of TAF8. In five further patients, the previously described c.781-1G > A mutation was present on both alleles. The clinical phenotype associated with the different TAF8 mutations is characterized by severe psychomotor retardation with almost absent development, feeding problems, microcephaly, growth retardation, spasticity and epilepsy. Cerebral imaging showed hypomyelination, a thin corpus callosum and brain atrophy. Moreover, repeated imaging in the sibling pair demonstrated progressive cerebral and cerebellar atrophy. Consistently, reduced N-acetylaspartate, a marker of neuronal viability, was observed on magnetic resonance spectroscopy. Further review of the literature shows that mutations causing a reduced expression of transcription factor II D subunits have an overlapping phenotype of microcephaly, developmental delay and intellectual disability. Although transcription factor II D plays an important role in RNA polymerase II transcription in all cells and tissues, the symptoms associated with such defects are almost exclusively neurological. This might indicate a specific vulnerability of neuronal tissue to widespread deregulation of gene expression as also seen in Rett syndrome or Cornelia de Lange syndrome.
- 27 June 2022
- Published by Oxford University Press (OUP) in Brain
- Vol. 145 (9) , 3022-3034
Mutations inTAF8cause a neurodegenerative disorder
TAF8 is part of the transcription factor II D complex, composed of the TATA-binding protein and 13 TATA-binding protein–associated factors (TAFs). Transcription factor II D is the first general transcription factor recruited at promoters to assemble the RNA polymerase II preinitiation complex. So far disorders related to variants in 5 of the 13 subunits of human transcription factor II D have been described. Recently, a child with a homozygous c.781-1G>A mutation in TAF8 has been reported. Here we describe seven further patients with mutations in TAF8 and thereby confirm the TAF8 related disorder. In two sibling patients, we identified two novel compound heterozygous TAF8 splice site mutations, c.45+4A > G and c.489G>A, which cause aberrant splicing as well as reduced expression and mislocalization of TAF8. In five further patients, the previously described c.781-1G > A mutation was present on both alleles. The clinical phenotype associated with the different TAF8 mutations is characterized by severe psychomotor retardation with almost absent development, feeding problems, microcephaly, growth retardation, spasticity and epilepsy. Cerebral imaging showed hypomyelination, a thin corpus callosum and brain atrophy. Moreover, repeated imaging in the sibling pair demonstrated progressive cerebral and cerebellar atrophy. Consistently, reduced N-acetylaspartate, a marker of neuronal viability, was observed on magnetic resonance spectroscopy. Further review of the literature shows that mutations causing a reduced expression of transcription factor II D subunits have an overlapping phenotype of microcephaly, developmental delay and intellectual disability. Although transcription factor II D plays an important role in RNA polymerase II transcription in all cells and tissues, the symptoms associated with such defects are almost exclusively neurological. This might indicate a specific vulnerability of neuronal tissue to widespread deregulation of gene expression as also seen in Rett syndrome or Cornelia de Lange syndrome.
- 17 August 2020
- Published by Springer Nature in Nature Neuroscience
- Vol. 23 (10) , 1215-1228
A glycolytic shift in Schwann cells supports injured axons
Axon degeneration is a hallmark of many neurodegenerative disorders. The current assumption is that the decision of injured axons to degenerate is cell-autonomously regulated. Here we show that Schwann cells (SCs), the glia of the peripheral nervous system, protect injured axons by virtue of a dramatic glycolytic upregulation that arises in SCs as an inherent adaptation to axon injury. This glycolytic response, paired with enhanced axon–glia metabolic coupling, supports the survival of axons. The glycolytic shift in SCs is largely driven by the metabolic signaling hub, mammalian target of rapamycin complex 1, and the downstream transcription factors hypoxia-inducible factor 1-alpha and c-Myc, which together promote glycolytic gene expression. The manipulation of glial glycolytic activity through this pathway enabled us to accelerate or delay the degeneration of perturbed axons in acute and subacute rodent axon degeneration models. Thus, we demonstrate a non-cell-autonomous metabolic mechanism that controls the fate of injured axons.
- 17 August 2020
- Published by Springer Nature in Nature Neuroscience
- Vol. 23 (10) , 1215-1228
A glycolytic shift in Schwann cells supports injured axons
Axon degeneration is a hallmark of many neurodegenerative disorders. The current assumption is that the decision of injured axons to degenerate is cell-autonomously regulated. Here we show that Schwann cells (SCs), the glia of the peripheral nervous system, protect injured axons by virtue of a dramatic glycolytic upregulation that arises in SCs as an inherent adaptation to axon injury. This glycolytic response, paired with enhanced axon–glia metabolic coupling, supports the survival of axons. The glycolytic shift in SCs is largely driven by the metabolic signaling hub, mammalian target of rapamycin complex 1, and the downstream transcription factors hypoxia-inducible factor 1-alpha and c-Myc, which together promote glycolytic gene expression. The manipulation of glial glycolytic activity through this pathway enabled us to accelerate or delay the degeneration of perturbed axons in acute and subacute rodent axon degeneration models. Thus, we demonstrate a non-cell-autonomous metabolic mechanism that controls the fate of injured axons.
- Open Access
- 2 January 2018
- Published by Taylor & Francis in Communicative & Integrative Biology
- Vol. 11 (1) , e1433441
Multiple lines of inhibitory feedback on AKT kinase in Schwann cells lacking TSC1/2 hint at distinct functions of mTORC1 and AKT in nerve development
During nerve development, Schwann cells (SCs) build multilayered myelin sheaths around axons to accelerate nerve conduction. The mechanistic target of rapamycin complex 1 (mTORC1) downstream of PI3K/AKT signaling lately emerged as a central anabolic regulator of myelination. Using mutant mice with sustained mTORC1 hyperactivity in developing SCs we recently uncovered that mTORC1 impedes developmental myelination by promoting proliferation of immature SCs while antagonizing SC differentiation. In contrast, mTORC1 stimulates myelin production, rather than SC proliferation, in already differentiated SCs. Importantly, these diametrical mTORC1 functions were unmasked under settings of greatly suppressed AKT signaling. Here we demonstrate, inter alia, additional mechanisms of feedback inhibition of AKT by mTORC1, such as strikingly elevated PTEN levels in SCs with disruption of the mTORC1 inhibitory complex, TSC1/2. These data lead us to propose a model wherein mTORC1 and AKT have distinct roles in developing SCs that have to be precisely coordinated for normal myelinogenesis.
- 2 January 2018
- Published by Taylor & Francis in Communicative & Integrative Biology
- Vol. 11 (1) , e1433441
Open AccessMultiple lines of inhibitory feedback on AKT kinase in Schwann cells lacking TSC1/2 hint at distinct functions of mTORC1 and AKT in nerve development
During nerve development, Schwann cells (SCs) build multilayered myelin sheaths around axons to accelerate nerve conduction. The mechanistic target of rapamycin complex 1 (mTORC1) downstream of PI3K/AKT signaling lately emerged as a central anabolic regulator of myelination. Using mutant mice with sustained mTORC1 hyperactivity in developing SCs we recently uncovered that mTORC1 impedes developmental myelination by promoting proliferation of immature SCs while antagonizing SC differentiation. In contrast, mTORC1 stimulates myelin production, rather than SC proliferation, in already differentiated SCs. Importantly, these diametrical mTORC1 functions were unmasked under settings of greatly suppressed AKT signaling. Here we demonstrate, inter alia, additional mechanisms of feedback inhibition of AKT by mTORC1, such as strikingly elevated PTEN levels in SCs with disruption of the mTORC1 inhibitory complex, TSC1/2. These data lead us to propose a model wherein mTORC1 and AKT have distinct roles in developing SCs that have to be precisely coordinated for normal myelinogenesis.
- 13 December 2017
- Published by Wiley in The Anatomical Record
- Vol. 301 (5) , 862-886
Species Differences in the Organization of the Ventral Cochlear Nucleus
The mammalian cochlear nuclei (CN) consist of two major subdivisions, the dorsal (DCN) and ventral (VCN) nuclei. We previously reported differences in the structural and neurochemical organization of the human DCN from that in several other species. Here we extend this analysis to the VCN, considering both the organization of subdivisions and the types and distributions of neurons. Classically, the VCN in mammals is composed of two subdivisions, the anteroventral (VCA) and posteroventral cochlear nuclei (VCP). Anatomical and electrophysiological data in several species have defined distinct neuronal types with different distributions in the VCA and VCP. We asked if VCN subdivisions and anatomically defined neuronal types might be distinguished by patterns of protein expression in humans. We also asked if the neurochemical characteristics of the VCN are the same in humans as in other mammalian species, analyzing data from chimpanzees, macaque monkeys, cats, rats and chinchillas. We examined Nissl‐ and immunostained sections, using antibodies that had labeled neurons in other brainstem nuclei in humans. Nissl‐stained sections supported the presence of both VCP and VCA in humans and chimpanzees. However, patterns of protein expression did not differentiate classes of neurons in humans; neurons of different soma shapes and dendritic configurations all expressed the same proteins. The patterns of immunostaining in macaque monkey, cat, rat, and chinchilla were different from those in humans and chimpanzees and from each other. The results may correlate with species differences in auditory function and plasticity. Anat Rec, 301:862–886, 2018.
- 13 December 2017
- Published by Wiley in The Anatomical Record
- Vol. 301 (5) , 862-886
Species Differences in the Organization of the Ventral Cochlear Nucleus
The mammalian cochlear nuclei (CN) consist of two major subdivisions, the dorsal (DCN) and ventral (VCN) nuclei. We previously reported differences in the structural and neurochemical organization of the human DCN from that in several other species. Here we extend this analysis to the VCN, considering both the organization of subdivisions and the types and distributions of neurons. Classically, the VCN in mammals is composed of two subdivisions, the anteroventral (VCA) and posteroventral cochlear nuclei (VCP). Anatomical and electrophysiological data in several species have defined distinct neuronal types with different distributions in the VCA and VCP. We asked if VCN subdivisions and anatomically defined neuronal types might be distinguished by patterns of protein expression in humans. We also asked if the neurochemical characteristics of the VCN are the same in humans as in other mammalian species, analyzing data from chimpanzees, macaque monkeys, cats, rats and chinchillas. We examined Nissl‐ and immunostained sections, using antibodies that had labeled neurons in other brainstem nuclei in humans. Nissl‐stained sections supported the presence of both VCP and VCA in humans and chimpanzees. However, patterns of protein expression did not differentiate classes of neurons in humans; neurons of different soma shapes and dendritic configurations all expressed the same proteins. The patterns of immunostaining in macaque monkey, cat, rat, and chinchilla were different from those in humans and chimpanzees and from each other. The results may correlate with species differences in auditory function and plasticity. Anat Rec, 301:862–886, 2018.
- 30 November 2017
- Published by Springer Nature in Brain Structure and Function
- Vol. 223 (4) , 1-15
Individual variability in the structural properties of neurons in the human inferior olive
The inferior olive (IO) is the sole source of the climbing fibers innervating the cerebellar cortex. We have previously shown both individual differences in the size and folding pattern of the principal nucleus (IOpr) in humans as well as in the expression of different proteins in IOpr neurons. This high degree of variability was not present in chimpanzee samples. The neurochemical differences might reflect static differences among individuals, but might also reflect age-related processes resulting in alterations of protein synthesis. Several observations support the latter idea. First, accumulation of lipofuscin, the “age pigment” is well documented in IOpr neurons. Second, there are silver- and abnormal tau-immunostained intraneuronal granules in IOpr neurons (Ikeda et al. Neurosci Lett 258:113–116, 1998). Finally, Olszewski and Baxter (Cytoarchitecture of the human brain stem, Second edn. Karger, Basel, 1954) observed an apparent loss of IOpr neurons in older individuals. We have further investigated the possibility of age-related changes in IOpr neurons using silver- and immunostained sections. We found silver-labeled intraneuronal granules in neurons of the IOpr in all human cases studied (n = 17, ages 25–71). We did not, however, confirm immunostaining with antibodies to abnormal tau. There was individual variability in the density of neurons as well as in the expression of the calcium-binding protein calretinin. In the chimpanzee, there were neither silver-stained intraneuronal granules nor irregularities in immunostaining. Overall, the data support the hypothesis that in some, but not all, humans there are functional changes in IOpr neurons and ultimately cell death. Neurochemical changes of IOpr neurons may contribute to age-related changes in motor and cognitive skills mediated by the cerebellum.
- 30 November 2017
- Published by Springer Nature in Brain Structure and Function
- Vol. 223 (4) , 1-15
Individual variability in the structural properties of neurons in the human inferior olive
The inferior olive (IO) is the sole source of the climbing fibers innervating the cerebellar cortex. We have previously shown both individual differences in the size and folding pattern of the principal nucleus (IOpr) in humans as well as in the expression of different proteins in IOpr neurons. This high degree of variability was not present in chimpanzee samples. The neurochemical differences might reflect static differences among individuals, but might also reflect age-related processes resulting in alterations of protein synthesis. Several observations support the latter idea. First, accumulation of lipofuscin, the “age pigment” is well documented in IOpr neurons. Second, there are silver- and abnormal tau-immunostained intraneuronal granules in IOpr neurons (Ikeda et al. Neurosci Lett 258:113–116, 1998). Finally, Olszewski and Baxter (Cytoarchitecture of the human brain stem, Second edn. Karger, Basel, 1954) observed an apparent loss of IOpr neurons in older individuals. We have further investigated the possibility of age-related changes in IOpr neurons using silver- and immunostained sections. We found silver-labeled intraneuronal granules in neurons of the IOpr in all human cases studied (n = 17, ages 25–71). We did not, however, confirm immunostaining with antibodies to abnormal tau. There was individual variability in the density of neurons as well as in the expression of the calcium-binding protein calretinin. In the chimpanzee, there were neither silver-stained intraneuronal granules nor irregularities in immunostaining. Overall, the data support the hypothesis that in some, but not all, humans there are functional changes in IOpr neurons and ultimately cell death. Neurochemical changes of IOpr neurons may contribute to age-related changes in motor and cognitive skills mediated by the cerebellum.
- 24 August 2017
- Published by Taylor & Francis in Cell Cycle
- Vol. 16 (18) , 1637-1638
mTORC1 promotes Schwann cell cycling and myelinogenesis
- 24 August 2017
- Published by Taylor & Francis in Cell Cycle
- Vol. 16 (18) , 1637-1638
mTORC1 promotes Schwann cell cycling and myelinogenesis
- 8 May 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (21) , E4261-E4270
mTORC1 promotes proliferation of immature Schwann cells and myelin growth of differentiated Schwann cells
Significance: The myelination of axons is essential for neuronal wiring and normal nervous system functions. In the peripheral nervous system, Schwann cells (SCs) form myelin sheaths around axons during nerve development. Such myelination is compromised in a number of diseases. Hence, identification and understanding of the key pathways regulating SC development and myelinogenesis are essential for therapeutic progress. Here we uncover two separate roles of the cellular signaling node mTORC1 (mechanistic target of rapamycin complex 1) for regulating the development of SCs and subsequently the growth of myelin sheaths. Moreover, we demonstrate that defective SCs possess a remarkable plasticity to remyelinate axons via mTORC1. Thus, manipulating mTORC1 activity in diseased SCs could be therapeutically beneficial.
- 8 May 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (21) , E4261-E4270
mTORC1 promotes proliferation of immature Schwann cells and myelin growth of differentiated Schwann cells
Significance: The myelination of axons is essential for neuronal wiring and normal nervous system functions. In the peripheral nervous system, Schwann cells (SCs) form myelin sheaths around axons during nerve development. Such myelination is compromised in a number of diseases. Hence, identification and understanding of the key pathways regulating SC development and myelinogenesis are essential for therapeutic progress. Here we uncover two separate roles of the cellular signaling node mTORC1 (mechanistic target of rapamycin complex 1) for regulating the development of SCs and subsequently the growth of myelin sheaths. Moreover, we demonstrate that defective SCs possess a remarkable plasticity to remyelinate axons via mTORC1. Thus, manipulating mTORC1 activity in diseased SCs could be therapeutically beneficial.